A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus

Poornima R; BRIGIDA S; Arul Amutha Elizabeth L; Soujania singh G; Tanuja Lella

doi:10.47750/pnr.2022.13.02.002

2022, Vol: 13, Issue: 2

13/2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

« Previous Article

Original Article

PNR. 2022; 13(2): 7-12

doi: 10.47750/pnr.2022.13.02.002

A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus

Poornima R, BRIGIDA S, Arul Amutha Elizabeth L, Soujania singh G, Tanuja Lella.

Abstract
INTRODUCTION: Diabetes mellitus is a metabolic disorder characterised by hyperglycaemia and abnormalities in simple carbohydrate, fat, and protein metabolism. Diabetes mellitus control can only be achieved by diet, exercise, regular sleep pattern then with addition of anti-hyperglycemic drugs like metformin, if glycated hemoglobin (HbA1C) is above 7.0%. MATERIALS & METHODS: The study period was from April 2019 September 2019. The total duration of study was 24 weeks. Total 160 patients were screened; among them 100 participants were selected as per the inclusion criteria. RESULTS: Out of 100 patients, only 91 patients have completed the study. Having perceived so much about the weightage of monotherapy with metformin, this study revealed the non-inferiority of dual therapy. CONCLUSION: To conclude dipeptidyl peptidase-4(DPP-4) inhibitor Teneligliptin 20mg OD with Metformin 500mg two times a day (BD) serves the purpose of enhancing the glycaemic control and stands to be an efficacious treatment of type 2 diabetes mellitus with better compliance and acceptability.

Key words: Metformin Monotherapy, Non-inferiority study, Teneligliptin and metformin dual therapy, Type 2 Diabetes Mellitus.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Poornima R Articles by BRIGIDA S Articles by Arul Amutha Elizabeth L Articles by Soujania singh G Articles by Tanuja Lella
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

R P, S B, L AAE, G Ss, Lella T. A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. PNR. 2022; 13(2): 7-12. doi:10.47750/pnr.2022.13.02.002

Web Style

R P, S B, L AAE, G Ss, Lella T. A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. https://www.pnrjournal.com/?mno=138754 [Access: August 11, 2022]. doi:10.47750/pnr.2022.13.02.002

AMA (American Medical Association) Style

R P, S B, L AAE, G Ss, Lella T. A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. PNR. 2022; 13(2): 7-12. doi:10.47750/pnr.2022.13.02.002

Vancouver/ICMJE Style

R P, S B, L AAE, G Ss, Lella T. A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. PNR. (2022), [cited August 11, 2022]; 13(2): 7-12. doi:10.47750/pnr.2022.13.02.002

Harvard Style

R, P., S, . B., L, . A. A. E., G, . S. s. & Lella, . T. (2022) A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. PNR, 13 (2), 7-12. doi:10.47750/pnr.2022.13.02.002

Turabian Style

R, Poornima, BRIGIDA S, Arul Amutha Elizabeth L, Soujania singh G, and Tanuja Lella. 2022. A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. Journal of Pharmaceutical Negative Results, 13 (2), 7-12. doi:10.47750/pnr.2022.13.02.002

Chicago Style

R, Poornima, BRIGIDA S, Arul Amutha Elizabeth L, Soujania singh G, and Tanuja Lella. "A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus." Journal of Pharmaceutical Negative Results 13 (2022), 7-12. doi:10.47750/pnr.2022.13.02.002

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

R, P., S, . B., L, . A. A. E., G, . S. s. & Lella, . T. (2022) A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. Journal of Pharmaceutical Negative Results, 13 (2), 7-12. doi:10.47750/pnr.2022.13.02.002

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The articles in Journal of Pharmaceutical Negative Results are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

Copyright � 2022 Journal of Pharmaceutical Negative Results All Rights Reserved. Subject to change without notice from or liability to Journal of Pharmaceutical Negative Results. For best results, please use Internet Explorer or Google Chrome	Contact Information ResearchTrentz Scientific Research Community Contact US 21, First Floor,ResearchTrentz (Registred Office) Thamotharan Street,India Email : editorial@pnrjournal.com, Support : pnrjournal@gmail.com

Contact Information

How to cite this article